October 17, 2007 - Positron Corp. introduced its dedicated Cardiac PET system that is expected to receive 510k FDA approval in spring 2008, at the annual meeting of the American Society of Nuclear Cardiology, held Sept. 6 to Sept. 9 in San Diego, CA.
Positron intends to be the first company to offer absolute coronary flow reserve calculations developed by K. Lance Gould, M.D. According to the company, Dr. Gould is considered the founder of Cardiac PET combined with the discovery of flow reserve in human studies.
The new PET-only molecular imaging system reportedly costs less than $600,000.
For more information: www.positron.com
July 25, 2024 
